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Abstract
The complications of decompensated cirrhosis are well documented and include variceal bleeding, fluid retention, and hepatic 
encephalopathy. A less well recognized complication of cirrhosis is muscle wasting or sarcopenia. It is now recognized to have a 
significant impact on patient survival, especially in patients who are awaiting liver transplantation. An understanding of the 
pathophysiology of muscle protein homeostasis has led to several proposed mechanisms of sarcopenia and the potential to 
reverse muscle loss. This review discusses the potential mechanisms of sarcopenia and highlights the possible future means of 
reversing sarcopenia.
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Introduction
Malnutrition is a common finding in end-stage liver disease 
(ESLD) (1), leading to a loss of muscle mass and an increase in 
frailty. The causes of malnutrition include inadequate dietary 
intake, anorexia, malabsorption, low salt and protein diets 
offered, and the complications of ESLD such as encephalopa-
thy and ascites. ESLD patients with malnutrition have longer 
hospital stays, increased hepatic complications, and in-hospital 
mortality (2). Loss of muscle mass, sarcopenia, is not 
 synonymous with malnutrition although they often overlap. 
Sarcopenia is a common complication of cirrhosis and is fre-
quently overlooked. It is defined as a reduction in the skeletal 
muscle mass and strength. It is often not addressed as  a 
 prognostic factor in ESLD or in patients assessed for 
liver transplantation. The mechanisms behind the cause of sar-
copenia are not fully understood, but it is a complication that 
adversely affects ESLD patient’s survival and quality of life. 
The prevalence of sarcopenia is higher than any other compli-
cations of ESLD. The mean prevalence is 48% compared to 
esophageal varices (10–15%), refractory ascites (−10%), or 
hepatocellular cancer (3, 4). There appears to be some gender 
and ethnicity factors in the development of sarcopenia, with it 
being more prevalent in Western societies (5). The prevalence 
of sarcopenia in cirrhosis is higher than any other gastrointes-
tinal disorder, being only 21% in patients with inflammatory 
bowel disease (4). The aim of this review is to assess the current 
state of knowledge of the mechanisms of muscle wasting in 
liver disease, diagnostic issues, and potential therapies.
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Body Composition and Muscle Physiology
In order to assess the loss of muscle mass, it is important to 
have an understanding of relative body composition and 
muscle physiology in a healthy individual. The assessment of 
body composition and of somatic protein stores relies on 
measuring the different body compartments, that is, water, 
fat, bone, muscle, and visceral organs. Body composition 
techniques aid in the diagnosis of protein depletion. Protein 
levels are usually preserved at the expense of fat utilization as 
an energy source. The amount of body fat compared to mus-
cle volume varies according to the cirrhotic stage. In compen-
sated cirrhotics, there is a high amount of body fat. While in 
decompensated cirrhotics there is a much lower amount of 
body fat, implying lipolysis occurring in the latter stages of 
cirrhosis is an alternative energy source (6). The utilization 
of fat thus spares muscle in the early stages of cirrhosis but as 
it becomes depleted glycogenesis in the muscle leads to a 
rapid muscle breakdown leading to sarcopenia. The assess-
ment of body composition ranges from simple anthropomet-
ric tests such as skin thickness to more complex measures 
such as bioelectrical impedance. Measuring such composi-
tion is essential when evaluating malnutrition and sarcopenia 
in liver patients.
The homeostasis of muscle bulk is tightly regulated requir-
ing a balance between muscle protein synthesis and muscle 
proteolysis. Muscle protein synthesis and muscle satellite cell 
recruitment are important factors in maintaining muscle 
bulk. The major pathway regulating protein synthesis is the 
exercise activation of mammalian target of rapamycin 
(mTOR). Recent evidence suggests that exercise increases 
intracellular calcium levels triggering both mTOR and mito-
gen-activated protein kinase (MAPK) to stimulate muscle 
protein formation (7). Other suggested stimuli of muscle pro-
tein production include insulin-like growth factor (IGF-1), 
insulin, leucine, testosterone (8), and interleukin (1).
Muscle replacement requires the activation and recruit-
ment of muscle satellite cells, the adult stem cell of skeletal 
muscle located between the sarcolemma and basal lamina 
within the muscle tissue. When activated they proliferate to 
expand the population of myoblasts and differentiate into 
myotubes capable of fusing together to form new myofibers.
Muscle protein synthesis and satellite cell recruitment are 
negatively controlled by the cytokine myostatin. Myostatin 
belongs to the transforming growth factor beta family. Acting 
in a paracrine fashion, its action is via a linkage with activ-
in(s), which is a type 2 transmembrane receptor leading to a 
serine threonine kinase phosphorylation of Smad2/3 that in 
turn transcriptionally regulates target genes responsible for 
muscle protein synthesis. To maintain muscle homeostasis, 
myostatin levels are regulated by follistatin, a widely expressed 
glycoprotein acting as an extracellular ligand trap to regulate 
the availability of myostatin and activins. Its actions are to 
increase/activate satellite cell recruitment and inhibit 
Smad2/3, thereby negating the action of myostatin. In exper-
imental models, follistatin infusions increase muscle protein 
synthesis leading to muscle hypertrophy (9).
Muscle breakdown or proteolysis is driven by two path-
ways: ubiquitin–proteasome pathway (UPP) and the autoph-
agy system. UPP is the major proteolysis pathway. Muscle 
protein is conjugated with ubiquitin, then degraded by 26S 
proteasome and removed. UPP can be induced by inactivity, 
injury, and inflammation driven by tumor necrosis factor 
(TNF), whereas it can be inhibited by protein kinase B. 
Autophagy contributes to cell homeostasis removing mis-
folded proteins and damaged organelles by the formation of 
autophagasome, which in turn delivers its contents to lyso-
somes for degradation. A factor in controlling autophagy 
rate is mTOR. Rapamycin has been demonstrated to stimu-
late autophagy by inhibiting mTOR. Thus myostatin, which 
inhibits mTOR, probably increases muscle proteolysis as a 
consequence of autophagy stimulation. An ongoing trial of 
leucine-enriched essential amino acid mixture seeks to 
demonstrate a reduction in autophagia and thus improve 
hepatic sarcopenia as leucine is a direct stimulant of mTOR 
(Clinical trials identifier NCT03208868).
Potential Mechanisms of Sarcopenia
Dysregulated muscle proteostasis in ESLD may result from a 
number of factors including cirrhosis being a metabolic star-
vation disorder, hormonal dysfunction (i.e., reduced testos-
terone), defective ureagenesis, alterations in branched chain 
amino acids, and a chronic inflammatory response to endo-
toxemia leading to elevated levels of TNF. This leads to an 
imbalance between muscle protein synthesis and proteolysis 
being disrupted in favor of proteolysis. As one may expect, 
there is marked interplay between the various potential 
mechanisms of sarcopenia. A considerable amount of 
research has concentrated on defective ureagenesis leading to 
elevated levels of ammonia or hyperammonemia. Ammonia 
is derived from purine, amino acid, and gut bacteria metabo-
lism. In the face of a reduction of the number of effective 
hepatocytes, which are metabolically distressed, as a conse-
quence of cirrhosis and portal hypertension leading to porto-
caval shunting, ammonia levels are raised in cirrhosis to 
cytotoxic levels. As the cirrhotic liver is unable to metabolize 
ammonia, skeletal muscle uptake of ammonia increases 
where it is converted to glutamine via a glutamate pathway. 
Within the skeletal muscle, excess ammonia induces transreg-
ulation of myostatin by a NF-kappa-mediated mechanism 
(10). Myostatin is a primary inhibitor of protein synthesis 
and increases autophagy leading to accelerated sarcopenia. 
It  is well established that myostatin levels are increased in 
 cirrhosis (11).
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The resultant detoxification of ammonia within the mito-
chondria leads to high levels of glutamine in the circulation. 
This is utilized by other peripheral tissues generating another 
source of ammonia thus maintaining the need for skeletal 
muscle to continually metabolize it. The biochemical step 
to convert ammonia to glutamate requires the tricarboxylic 
acid cycle intermediary alpha-ketoglutarate. The constant 
demand for it eventually leads to its depletion resulting in 
mitochondrial dysfunction and consequently decreased 
 protein synthesis. In addition, the mitochondria become 
increasingly leaky generating reactive oxidative species 
 further inducing autophagy and proteolysis (12, 13). 
Hyperammonemia, and the resultant intracellular amino 
acid deficiency, further stresses the cell resulting in a reduc-
tion of mRNA translation and protein synthesis, which 
occurs via a eukaryotic initiation factor (eIF2) alpha kinase, 
general control nondepressed two (GCN2) pathway (12–15).
Due to cirrhosis being a state of accelerated starvation, 
and with the reduction in available branched chain amino 
acids (BCCA) because of their role in anaplerosis, it has also 
been suggested that muscle synthesis is restricted as amino 
acids are diverted to other cells for the synthesis of other crit-
ical amino acids such as albumin (16). Reduced cellular 
amino acid concentrations also activate increased skeletal 
muscle autophagy in cirrhosis (17). Hormonal disarray may 
also play a role in sarcopenia. Both testosterone and growth 
hormone are known to inhibit myostatin expression and 
 signaling (18, 19). In cirrhosis, both are reduced and there-
fore may contribute to decreased muscle protein synthesis 
(20, 21).
In addition to being a starvation disorder, cirrhosis is also 
a state of chronic endotoxemia leading to increased circulat-
ing levels of TNF. TNF has been shown to impair muscle 
synthesis, activate autophagy, and inhibit hormones such as 
growth hormone and IGF-1 (22–24).
Diagnosis of Sarcopenia in Cirrhosis
A full dietary survey should be undertaken to address 
any concomitant malnutrition. Bioelectrical impedance anal-
ysis, dual energy X-ray absorptiometry (DEXA), and air dis-
placement plethismography reflect indirect measures of 
muscle mass (25). CT and MRI are now the recommended 
investigations offering both sensitive and specific measure of 
adiposity and muscle mass. Measurement of peripheral mus-
cle mass is not acceptable due to changes in muscle bulk asso-
ciated with activity. Evaluation of psoas and paraspinal 
muscles using CT at the level of the third lumbar vertebra 
(L3) is a more reproducible means of sequentially following 
muscle bulk.
The definition of sarcopenia in patients with cirrhosis 
lacks a consensus regarding adequate cut-off  values. Most 
studies defining sarcopenia use the L3 skeletal mass index 
cut-off  values suggested by Prado (L3 SMI: ≤ 38.5 cm2/m2 for 
women and ≤ 52.4 cm2/m2 for men) (26). However, both CT 
and MRI have limited access in routine practice (27). 
Recently, the use of the combination of body mass index and 
thigh muscle thickness measured by ultrasound has been 
shown to be almost as good as CT in assessing cirrhotic sar-
copenia and may offer a cheaper more accessible means of 
diagnosing sarcopenia (28).
Potential Treatments of Sarcopenia
There are no definitive therapies to reverse cirrhotic sarcope-
nia. Attempts at improving muscle mass by means of nutri-
tional support, increasing exercise, and correcting hormonal 
disarray have proved disappointing although reducing 
ammonia levels and myostatin levels are promising in some 
studies.
General nutritional support
The caloric and protein intake in ESLD is usually reduced 
due to alterations in taste, anorexia, salt restriction, and 
impaired gut motility leading to a relative malabsorptive state 
(29). This lack of intake accelerates the state of metabolic 
starvation in patients. Several studies of enteral and paren-
teral feeding have not shown any improvement in muscle 
mass, nutritional status, nitrogen retention, or survival (30). 
Only a single study of high energy–high protein supplemen-
tation was able to demonstrate significant nitrogen retention. 
The utilization of a multidisciplinary nutrition support team 
and patient education appears to benefit quality of life and 
improve survival (31). The timing of nutritional support 
appears to be important. Evidence suggests that a late eve-
ning snack and an early morning protein supplement are the 
most likely to stabilize muscle homeostasis (32). The amounts 
of caloric and protein intake are well documented in the 
European Association for Study of the Liver (EASL) Clinical 
Practice guidelines on nutrition in chronic liver disease (33).
Exercise
Exercise stimulates muscle protein synthesis through the acti-
vation of mTOR but whether this pathway in cirrhosis is 
inhibited by hyperammonemia and elevated myostatin is 
unknown. There is evidence that hyperammonemia alters 
muscle function by altering contractile function and increas-
ing muscle fatigue in patients with ESLD (34). Exercise gen-
erates muscle ammonia, which may negate any potential 
muscle protein synthesis (35). Despite these theoretical con-
siderations, a combination of moderate intensity resistance 
and endurance exercise may benefit sarcopenia in ESLD (36). 
A recent study has suggested that a combination of BCAA 
supplementation and walking exercise improved muscle vol-
ume and hand grip strength which if  confirmed could be eas-
ily implemented (37).
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Branched chain amino acid supplementation
In ESLD, it is well established that there is a decrease in 
BCAA and an increase in aromatic amino acids (AAA) 
which may contribute to hepatic encephalopathy (HE) 
(38, 39). The role of BCAA therapy in HE is not established 
with some trials showing no benefit, while a recent Cochrane 
review favors benefit (40–42). A further study of BCAA 
 supplementation in HE suggests that minimal HE can be pre-
vented and interestingly muscle mass can be recovered (43). 
BCAA may be of benefit by acting as a substrate for anaple-
rosis in the alpha-ketoglutamate, Glutamine–glutamate path-
way in muscle, and thereby remove ammonia. A further 
potential mechanism of BCAA therapy maybe to act as an 
inhibitor of the amino acid deficiency sensor GCN2 and 
reverse eIF2 phosphorylation leading to an increase in mus-
cle synthesis (44). The specific use of leucine-rich amino acid 
supplementation stimulates mTOR activation leading to 
higher rate of protein synthesis via messenger RNAs 
(mRNA) (45–47). If  mTOR signaling is impaired, autophagy 
is increased in cirrhosis, and it has been shown that this can 
be reversed by an enriched leucine BCAA supplementation. 
In addition, the study suggested the reversal of the GNC2/
eIF2 pathway (48).
Anabolic Hormones
Testosterone, growth hormone, and insulin-like growth fac-
tor-1 (IGF-1) are known to influence muscle protein synthe-
sis by activating mTOR and suppressing myostatin (49). 
These anabolic hormones are reduced in cirrhosis (50) but 
studies have not shown any definitive benefit in cirrhotic sar-
copenia. In a rat model of cirrhosis, IGF-1 treatment has 
been shown a decrease in myostatin and improved nitrogen 
retention (51, 52). Recently, Nutmeg extract has been demon-
strated to increase skeletal muscle mass in the elderly acting 
via the IGF-1, protein kinase B(AKT), and mTOR pathway 
inhibiting autophagy (53). Whether this could be applied to 
ESLD patients with sarcopenia begs further clinical studies. 
Testosterone trials in reversing sarcopenia have been incon-
clusive, although one small study demonstrated improved 
hand grip (54). A further study of men with cirrhosis was 
able to show an increase in bone mass and muscle mass, and 
a reduction in the fat mass (55).
Ammonia Lowering Therapy
Reducing ammonia levels may potentially reverse sarcopenia. 
However, sarcopenia continues to be a problem following 
liver transplantation which should correct the metabolic 
changes of ESLD (56) It has been suggested that the use of 
post-transplant immunosuppressant drugs, such as cyclospo-
rine A and mTOR inhibitors, may be responsible for the 
ongoing sarcopenia (3, 57). In a recent animal model of por-
tal hypertension, the use of rifaximin and l-orthenine 
l-aspartate (LOLA) for 4 weeks was seen to restore muscle 
proteostasis and reverse sarcopenia. The treatment was seen 
to downregulate the ammonia-induced myostatin produc-
tion, reverse autophagy, and partially reverse GCN2/eIF2 
pathway activity. As lowering of ammonia is an established 
therapy for hepatic encephalopathy, long-term clinical stud-
ies of such therapy are now indicated (12).
Myostatin inhibition
Myostatin inhibitors have the potential to promote muscle 
protein synthesis although no human data are available. 
Recently, antibodies to myostatin and its precursor pro- 
myostatin have been shown in rats and non-human primates 
to inhibit myostatin activity and induce muscle anabolic 
activity. Similar results in non-human primates have been 
found with domagrozumab therapy (58, 59). The use of 
recombinant follistatin-288 has been shown to promote 
growth of skeletal muscle (9).
Prognosis of Sarcopenia
The overall rate of mortality in cirrhotic patients is 12.5 in 
every 100,000 patients (60). With the onset of sarcopenia, 
there is a threefold increase in mortality compared to cir-
rhotic patients without sarcopenia (61). Sarcopenia is an 
independent prognostic indicator for patients awaiting liver 
transplantation with estimated survival rates at 1, 2, and 
3 years being 63%, 51%, and 51%, respectively, compared to 
nonsarcopenic patients with survival rates of 79%, 74%, and 
70% over a similar period (62).
A number of studies have identified sarcopenia to be a 
prognostic factor in the increased mortality of patients await-
ing liver transplantation. In a study of 232 consecutive trans-
plant recipients, sarcopenia increased the length of hospital 
stay, intensive care unit (ICU) stay, and 12-month mortality; 
6% of the sarcopenic patients did not survive the 12-month 
period (63). A meta-analysis comparing patients with sarco-
penia and non-sarcopenia demonstrated an increased mor-
tality by 3.25% for patients with ESLD and sarcopenia. The 
sarcopenia patients also had an increased complication rate 
in post-transplant infections, sepsis, and mechanical ventila-
tion periods compared to non-sarcopenia patients who were 
less likely to experience these complications. The analysis 
highlights that due to sarcopenia’s significant influence on 
mortality and complications, it is an important prognostic 
factor, independent of the current model of end-stage liver 
disease (MELD) and Child-Turcotte-Pugh (CTP) scores 
used (4).
A large retrospective study of sarcopenia-related ESLD 
(64) found that paraspinal muscles index (PSMI) seems to be 
the most reliable diagnostic aid in predicting transplant 
 outcomes. Its use not only predicts death but also estimates 
associated complications for patients on the transplant 
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waiting list. This study supports Kalafateli et al.’s paper, and 
in that it calculates the improved outcomes of patients per 
unit of improved muscle mass.
The traditional MELD score does not incorporate sarco-
penia as a factor of assessment. The evidence above and 
many other existing studies support that sarcopenia is, in 
itself, a prognostic indicator of survival for ESLD patients. 
A  more recent modified version, known as the MELD-
sarcopenia score, has been proposed, offering a better 
 prognostic value for patients awaiting or undergoing liver 
transplant. Therefore, consideration and management of 
skeletal muscle may improve transplantation outcomes.
Conclusion
Sarcopenia is a common and significant complication of cir-
rhosis. It is a prevalent and important issue to address in 
patient’s awaiting liver transplant, as sarcopenia greatly 
increases mortality. There have been multiple hypotheses pro-
posed regarding the mechanism(s) underlying sarcopenia in 
order to determine an effective treatment. This includes 
defective ureagenesis with ammonia elevation, alterations in 
BCAA, and chronic inflammatory response with the presence 
of elevated TNF leading to increased proteolysis. Based on 
these hypotheses, interventions have been attempted with 
some promising results, including nutrition support, exercise 
focused on resistance and endurance, and BCAA supplemen-
tation. Targeting ammonia has also shown to have benefits 
on sarcopenia, especially with the use of rifaximin and LOLA 
restoring muscle proteostasis, potentially reversing sarcope-
nia. Although transplant remains the only curative treat-
ment, patients with significant sarcopenia are less likely to 
survive transplant. Efforts should focus on improving muscle 
mass and nutrition in these patients prior to surgery. 
Increasing the awareness of sarcopenia should improve the 
prognosis and quality of life of patients with ESLD.
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